The 2-oxopyrrolidinacetamide piracetam reduces infarct brain volume induced by permanent middle cerebral artery occlusion in male rats

被引:21
作者
Tortiglione, A [1 ]
Minale, M [1 ]
Pignataro, G [1 ]
Amoroso, S [1 ]
DiRenzo, G [1 ]
Annunziato, L [1 ]
机构
[1] Univ Naples Federico II, Sch Med, Nurosci Dept, Pharmacol Sect, I-80131 Naples, Italy
关键词
piracetam; pMCAO; infarct volume;
D O I
10.1016/S0028-3908(02)00093-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this study, the temporal development of focal cerebral infarction induced by permanent middle cerebral artery occlusion (pMCAO) and the effects of piracetam, a derivative of gamma-aininobutyric acid widely used in clinical practice as a nootropic agent, on infarct area and volume were investigated. pMCAO caused a cerebral infarct whose size progressively increased after 3, 6, 9, and 24 h. Piracetam (125 mg/ka i.p.), administered 6, 9, and 22 h after pMCAO, did not reduce pMCAO-induced brain infarct area size detected at the 24th hour. By contrast, when this agent was administered at the doses of 250 and 500 mg/kg, it caused a marked reduction of the infarct area size. This reduction was observed in almost every brain slice affected by pMCAO, although statistical differences (p <0.05) were detected in slices located at 3-5.5 mm posterior to the anterior pole in animals treated with 250 mg/kg piracetam and in slices located at 3.5-5 mm in those receiving 500 mg/kg. When the mean total volumes of brain infarct resulting from pMCAO were calculated, it was observed that in animals which had received piracetam (250 or 500 mg/kg) infarction volume was markedly (50%) and significantly (p <0.05) reduced in comparison with saline injected rats. Finally, piracetam (250 mg/kg administered i.p. 6, 9, and 22 h after the ischemic insult) significantly reduced brain infarct area evaluated 48 h and 7 days after pMCAO. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 26 条
[1]   THRESHOLDS IN CEREBRAL-ISCHEMIA - THE ISCHEMIC PENUMBRA [J].
ASTRUP, J ;
SIESJO, BK ;
SYMON, L .
STROKE, 1981, 12 (06) :723-725
[2]   EVALUATION OF 2, 3, 5-TRIPHENYLTETRAZOLIUM CHLORIDE AS A STAIN FOR DETECTION AND QUANTIFICATION OF EXPERIMENTAL CEREBRAL INFARCTION IN RATS [J].
BEDERSON, JB ;
PITTS, LH ;
GERMANO, SM ;
NISHIMURA, MC ;
DAVIS, RL ;
BARTKOWSKI, HM .
STROKE, 1986, 17 (06) :1304-1308
[3]   INFLUENCE OF AGING AND EXOGENOUS SUBSTANCES ON CEREBRAL ENERGY-METABOLISM IN POSTHYPOGLYCEMIC RECOVERY [J].
BENZI, G ;
PASTORIS, O ;
VILLA, RF ;
GIUFFRIDA, AM .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (09) :1477-1483
[4]  
BERING B, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1350
[5]  
CHOI DW, 1990, J NEUROSCI, V10, P2493
[6]   Acute reorganization of the forepaw representation in the rat SI cortex after focal cortical injury: neuroprotective effects of piracetam treatment [J].
Coq, JO ;
Xerri, C .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (08) :2597-2608
[7]   OXIDATIVE STRESS, GLUTAMATE, AND NEURODEGENERATIVE DISORDERS [J].
COYLE, JT ;
PUTTFARCKEN, P .
SCIENCE, 1993, 262 (5134) :689-695
[8]   Treatment of acute ischemic stroke with piracetam [J].
DeDeyn, PP ;
DeReuck, J ;
Deberdt, W ;
Vlietinck, R ;
Orgogozo, JM .
STROKE, 1997, 28 (12) :2347-2352
[9]  
DEPRESSEUX JC, 1986, EVALUATION EFFECTS P
[10]   EFFECT OF PIRACETAM ON RECOVERY AND REHABILITATION AFTER STROKE - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
ENDERBY, P ;
BROECKX, J ;
HOSPERS, W ;
SCHILDERMANS, F ;
DEBERDT, W .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 (04) :320-331